ICRT-5

• Description :

  ICRT-5 is a β-catenin-regulated transcription (CRT) inhibitor. iCRT-5 can block Wnt/β-catenin reporter activity and down regulate β-catenin expression. iCRT-5 can be used for the research of multiple myeloma[1][2].

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H312, H332

• Target :

  Wnt; β-catenin

• Type :

  Reference compound

• Related Pathways :

  Stem Cell/Wnt

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/icrt-5.html

• Purity :

  99.1

• Solubility :

  DMSO : 36 mg/mL (ultrasonic; warming)

• Smiles :

  O=C(O)CCCN(C/1=O)C(SC1=C/C2=CC=C(OC)C(OC)=C2)=S

• Molecular Formula :

  C16H17NO5S2

• Molecular Weight :

  367.44

• Precautions :

  H302, H312, H332

• References & Citations :

  [1]Käfer R, et, al. Inhibitors of β-catenin affect the immuno-phenotype and functions of dendritic cells in an inhibitor-specific manner. Int Immunopharmacol. 2016 Mar;32:118-124.|[2]Narayanan BA, et, al. Antagonistic effect of small-molecule inhibitors of Wnt/β-catenin in multiple myeloma. Anticancer Res. 2012 Nov;32 (11) :4697-707.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [18623-44-4]